PERTH, Australia – Australia is kicking off its first-ever registry-based randomized controlled trials in oncology to help clinicians select the right treatments for the right patients.
PERTH, Australia – Australia is kicking off its first-ever registry-based randomized controlled trials in oncology to help clinicians select the right treatments for the right patients.
PERTH, Australia – Dimerix Ltd. has begun recruiting patients for two separate phase II trials of its kidney disease candidate, DMX-200, in diabetic kidney disease and in orphan disease focal segmental glomerulosclerosis (FSGS). The Perth, Australia-based company hopes to replicate compelling data it saw in a subgroup of patients with type 2 diabetes, which could significantly open up the potential patient population for the drug.
PERTH, Australia – Dimerix Ltd. has begun recruiting patients for two separate phase II trials of its kidney disease candidate, DMX-200, in diabetic kidney disease and in orphan disease focal segmental glomerulosclerosis (FSGS). The Perth, Australia-based company hopes to replicate compelling data it saw in a subgroup of patients with type 2 diabetes, which could significantly open up the potential patient population for the drug.
PERTH, Australia – Adelaide-based Bionomics Ltd.'s lead candidate, BNC-210, failed to meet the primary endpoint of decreasing symptoms in patients with post-traumatic stress disorder (PTSD) in its phase II trial, and the company is stopping development in PTSD. Shares of Bionomics (ASX:BNO) closed Tuesday at A17 cents (US12 cents), down A33 cents, or 66 percent, on the news.
